Sutherland I, Springett V H
Medical Research Council Biostatistics Unit, Cambridge.
Tubercle. 1987 Jun;68(2):81-92. doi: 10.1016/0041-3879(87)90023-7.
The effectiveness of BCG vaccination, at about age 13 years, in the prevention of tuberculosis at ages 15-24 years in England and Wales in 1983, has been determined by the same method as in two previous surveys in 1973 and 1978. In 1983, the tuberculosis notification rate among those vaccinated in the schools' scheme was 3.30 per 100,000, compared with an estimated rate of 13.20 per 100,000 among those who were tuberculin negative and not vaccinated in the scheme. The protective effectiveness of BCG vaccination at ages 15-24 years in England and Wales in 1983 is thus estimated as 75%; the estimated efficacy in the white ethnic group is closely similar, namely 76%. The estimated efficacy of BCG at ages 15-19 and 20-24 years in the three surveys, both in the white ethnic group and in the entire cohort, has been compared with that found in the Medical Research Council's controlled trial of tuberculosis vaccines which began in 1950. There is no evidence of any decrease in the protective efficacy of BCG vaccination between the four cohorts of young adults, which span a total period of 29 years. However, there were steep decreases between the cohorts in the annual notification rates for the white ethnic group; these decreases occurred in the BCG vaccinated and in the tuberculin negative unvaccinated groups, as well as among those found tuberculin positive (and not vaccinated) in the schools' scheme. It is concluded that the level of protective efficacy of BCG vaccination at ages 15-24 years is high, and has remained unchanged since the start of the BCG in schools' scheme. However, as the tuberculosis notification rate in young adults has decreased steeply throughout this period, and is continuing to decrease, the benefits to be expected from the BCG in schools' scheme will decrease equally rapidly.
1983年,在英格兰和威尔士,通过与1973年和1978年之前两次调查相同的方法,确定了约13岁时接种卡介苗在预防15至24岁人群患结核病方面的有效性。1983年,学校接种计划中接种卡介苗人群的结核病通报率为每10万人3.30例,而结核菌素阴性且未参与该接种计划人群的估计通报率为每10万人13.20例。因此,1983年在英格兰和威尔士,15至24岁人群接种卡介苗的保护效力估计为75%;白人种族群体的估计效力与之相近,为76%。在这三项调查中,对白人种族群体和整个队列中15至19岁以及20至24岁人群接种卡介苗的估计效力,与医学研究委员会1950年开始的结核病疫苗对照试验中的结果进行了比较。没有证据表明在跨越29年的四组年轻成年人中,卡介苗接种的保护效力有任何下降。然而,白人种族群体的年度通报率在各队列之间急剧下降;这些下降发生在接种卡介苗的人群、结核菌素阴性未接种的人群以及学校计划中结核菌素呈阳性(且未接种)的人群中。得出的结论是,15至24岁人群接种卡介苗的保护效力水平很高,自学校实施卡介苗接种计划以来一直保持不变。然而,由于在此期间年轻成年人的结核病通报率急剧下降且仍在继续下降,学校卡介苗接种计划预期的益处也将同样迅速减少。